Can This Approach Help? Inside the Latest Research on Molecular tumor burden index as a response evaluation criterion in breast
The patients classified as molecular responders had longer progression-free survival and overall survival than the nonmolecular responders in the overall cohort (P < 0.001 and P = 0.036, respectively), as well as in the cohort...